NCT06947408View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

April 23, 2026

Study Completion Date

April 23, 2026

Conditions
Asthma
Interventions
DRUG

Placebo

Healthy participants and patients with asthma will receive matched placebo.

DRUG

IBI3002

Healthy participants and patients with asthma will receive IBI3002 at the corresponding dose and dosing interval.

Trial Locations (1)

100192

RECRUITING

China-japan Friendship Hosipital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06947408 - A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants | Biotech Hunter | Biotech Hunter